Monthly ibandronate versus weekly risedronate treatment for low bone mineral density in stable renal transplant patients

被引:9
|
作者
Sanchez-Escuredo, Ana [1 ]
Fuster, David [2 ]
Rubello, Domenico [4 ]
Muxi, Africa [2 ]
Ramos, Ana [3 ]
Campos, Francisco [2 ]
Marzola, Maria Cristina [4 ]
Cook, Gary J. [5 ]
Tapias, Andres [2 ]
Torregrosa, Jose-Vicente [1 ]
机构
[1] Hosp Clin Barcelona, Dept Nephrol & Renal Transplant, Barcelona, Spain
[2] Hosp Clin Barcelona, Dept Nucl Med, Barcelona, Spain
[3] Fdn Jimenez Diaz, Dept Nephrol, E-28040 Madrid, Spain
[4] Santa Maria Della Misericordia Hosp, Dept Nucl Med, I-45100 Rovigo, Italy
[5] Kings Coll London, Div Imaging Sci & Biomed Engn, Dept Canc Imaging, London, England
关键词
biphosphonates; bone mineral density; ibandronate; renal transplant; risedronate; BISPHOSPHONATES; OSTEOPOROSIS;
D O I
10.1097/MNM.0000000000000316
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
IntroductionBisphosphonates may aid in treating and preventing bone loss promoted by chronic immunosuppressive treatment and secondary hyperparathyroidism in renal transplant (RT) patients. However, the effectiveness of bisphosphonates is compromised by poor patient compliance. The objective of the study was to compare the effects of once monthly ibandronate with those of weekly risedronate administration on bone mineral density (BMD) and renal function in RT patients.Patients and methodsSixty-nine patients were prospectively recruited who were at least 12 months post-RT and were treated with either oral ibandronate 150mg monthly (n=35) or oral risedronate 35mg weekly (n=34). At baseline and 1 year, creatinine, calcium, alkaline phosphatase, and i-parathyroid hormone were measured, and BMD was determined by dual-energy X-ray absorptiometry.ResultsGroup I consisted of 35 patients (28 women) treated with ibandronate who were of a mean age of 6312 years. Group II consisted of 34 patients (30 women) treated with risedronate who were of a mean age of 64 +/- 10 years. Lumbar BMD was as follows: baseline T-score (group I vs. group II) of -1.7 +/- 0.8 versus -1.9 +/- 0.8 (P=NS); and annual T-score of -1.3 +/- 0.6 versus -1.4 +/- 0.8 (P=NS). After 1 year, lumbar BMD improved to reveal a T-score of -1.3 +/- 0.6 in the ibandronate group (P<0.01) and -1.4 +/- 0.8 in the risedronate group (P<0.01). Femoral BMD was as follows: baseline T-score (group I vs. group II) of -2.1 +/- 0.7 versus -2.2 +/- 0.6 (P=NS); and annual T-score of -1.8 +/- 0.9 versus -1.8 +/- 0.8 (P=NS). Cortical bone also improved in both groups, but results were not statistically significant. No changes in renal function and no adverse effects were observed.ConclusionIn RT patients with low BMD, no difference in effects on BMD, renal function, or adverse effects were observed between monthly oral ibandronate and weekly oral risedronate administration.
引用
收藏
页码:815 / 818
页数:4
相关论文
共 50 条
  • [21] THE RELATIONSHIP OF BONE MINERAL DENSITY AND VITAMIN K IN RENAL TRANSPLANT PATIENTS
    Senturk, Merve
    Catal, Sila
    Mentese, Ilay Berke
    Kaya, Burcu
    Atas, Dilek Barutcu
    Tugcu, Murat
    Asicioglu, Ebru
    Arikan, Izzet Hakki
    Tuglular, Z. Serhan
    Velioglu, Arzu
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I950 - I950
  • [22] ASSESSMENT OF LIPID PROFILES AND BONE MINERAL DENSITY IN RENAL TRANSPLANT PATIENTS
    Fernandez Castillo, Rafael
    Fernandez Gallegos, Ruth
    Pena Amaro, Maria Pilar
    Esteban de la Rosa, Rafael Jose
    NUTRICION HOSPITALARIA, 2015, 31 (06) : 2503 - 2510
  • [23] Continued improvements in bone mineral density observed from 1 to 2 years after treatment with monthly oral ibandronate
    Sunyecz, John
    Lewiecki, Michael
    Emkey, Ronald
    Barr, Charles
    Genant, Harold
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2006, 13 (06): : 1015 - 1015
  • [24] Once weekly alendronate produces a greater increase in bone mineral density than daily risedronate
    Hosking, D
    Adami, S
    Felsenberg, D
    Reginster, JY
    Cannata, J
    Välimäki, M
    Santora, A
    Yacik, C
    Zaru, L
    BONE, 2003, 32 (05) : S207 - S207
  • [25] Risedronate increases bone mineral density and is well-tolerated in postmenopausal women with low bone mineral density.
    Ribot, C
    Smith, R
    Fogelman, I
    Bettica, P
    Pack, S
    Ethgen, D
    Reginster, JY
    JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 : S136 - S136
  • [26] Risedronate reduces hip fractures in patients with low femoral neck bone mineral density.
    Miller, P
    Roux, C
    McClung, M
    Adami, S
    Eastell, R
    Pack, S
    Ethgen, D
    ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S287 - S287
  • [27] Efficacy and Safety of Monthly Oral Ibandronate in Postmenopausal Women with Low Bone Density.
    Bolognese, M. A.
    McClung, M. R.
    Sedarati, F.
    Recker, R. R.
    Miller, P. D.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2008, 23 : S339 - S339
  • [28] Effects of ibandronate on bone mineral density and microstructure in patients with primary osteoporosis after treatment with teriparatide
    Chiba, Ko
    Okazaki, Narihiro
    Shiraishi, Kazuteru
    Osaki, Makoto
    JOURNAL OF BONE AND MINERAL RESEARCH, 2019, 34 : 163 - 163
  • [29] EFFECTS OF WEEKLY RISEDRONATE WITH CHOLECALCIFEROLON 25-HYDROXYVITAMIN D LEVEL AND BONE MINERAL DENSITY IN KOREAN PATIENTS WITH OSTEOPOROSIS
    Chung, H. Y.
    Park, H. M.
    OSTEOPOROSIS INTERNATIONAL, 2015, 26 : S98 - S98
  • [30] HIGHER RESPONSE WITH BONE MINERAL DENSITY (BMD) INCREASE AND BONE TURNOVER REDUCTION FOLLOWING TREATMENT WITH MONTHLY INJECTABLE IBANDRONATE (IBN) FOR PATIENTS (PTS) WITH OSTEOPOROSIS IN THE MOVER STUDY
    Nakano, T.
    Nakamura, T.
    Ito, M.
    Hagino, H.
    Hashimoto, J.
    Tobinai, M.
    Mizunuma, H.
    OSTEOPOROSIS INTERNATIONAL, 2014, 25 : S229 - S229